DnD Assay: Fast Antibiotic Resistance Detection

The escalating crisis of antibiotic resistance isn’t a future threat – it’s a present reality, and recent research underscores a critical nuance: we’ve been significantly underestimating the problem. While traditional antibiotic resistance focuses on bacteria evolving mechanisms to outright defeat drugs, a growing body of evidence, synthesized from studies spanning decades (Martens & Demain, 2017; Currie et al., 2014), reveals the pervasive role of tolerance and heteroresistance. These phenomena aren’t about bacteria becoming immune; they’re about bacteria surviving antibiotic exposure in a dormant or less susceptible state, allowing them to rebound and potentially develop full resistance later. This isn’t simply a matter of semantics; it fundamentally alters how we approach treatment and surveillance.

The core issue lies in the complexity of bacterial populations. Standard antibiotic susceptibility testing (Clinical and Laboratory Standards Institute, 2025; European Committee on Antimicrobial Susceptibility Testing, 2003; Kowalska-Krochmal & Dudek-Wicher, 2021; Matuschek et al., 2014; Turnidge & Paterson, 2007) typically identifies the minimum inhibitory concentration (MIC) – the lowest concentration of an antibiotic that prevents visible growth. However, this doesn’t account for subpopulations within a bacterial culture that exhibit tolerance (Westblade et al., 2020; Deventer et al., 2024) or heteroresistance (Andersson et al., 2019; El-Halfawy & Valvano, 2015; Band & Weiss, 2019; Band et al., 2021). Tolerance represents a transient state where bacteria aren’t killed but their growth is slowed, allowing them to survive the antibiotic course. Heteroresistance, on the other hand, involves a genetically diverse population where a small fraction possesses resistance genes, while the majority are susceptible – but the resistant subpopulation can proliferate after antibiotic exposure (Pereira et al., 2021). Recent work highlights that heteroresistance is often underestimated due to the limitations of current detection methods (Band & Weiss, 2021; Blair et al., 2015).

The mechanisms driving these phenomena are multifaceted. Gene amplification (Nicoloff et al., 2019; Pal & Andersson, 2024) can lead to increased expression of resistance genes, while epigenetic inheritance (Motta et al., 2015) and genetic noise (Şimşek & Kim, 2019) contribute to phenotypic heterogeneity. Crucially, bacterial persistence – a non-genetic state of dormancy – plays a significant role (Balaban et al., 2004; Ronneau et al., 2021; Balaban et al., 2019). These tolerant or heteroresistant cells aren’t necessarily killed by antibiotics, allowing them to repopulate and potentially evolve full resistance (Levin-Reisman et al., 2017; Windels et al., 2019). Furthermore, factors like bacterial growth rate and metabolic state can influence susceptibility (Artemova et al., 2015; Deris et al., 2013; Alexander & MacLean, 2020). The interplay between virulence and resistance, particularly in opportunistic pathogens like Acinetobacter baumannii, adds another layer of complexity (Geisinger et al., 2018; Chandrapati & Williams, 2014).

The Forward Look: The implications are profound. Current clinical practices, relying heavily on MIC values, may be insufficient to predict treatment outcomes. We need a paradigm shift towards more sophisticated diagnostic tools. Single-cell analysis (Baltekin et al., 2017) offers a promising avenue, allowing for the detection of heteroresistance and tolerance at the individual cell level. However, widespread implementation is currently limited by cost and complexity. More immediately, a greater emphasis on stewardship programs – optimizing antibiotic use to minimize selective pressure – is critical. Furthermore, research into novel therapeutic strategies that target persister cells or disrupt tolerance mechanisms is urgently needed. Expect to see increased investment in rapid diagnostics capable of identifying these subtle resistance phenotypes, and a move away from solely relying on traditional culture-based susceptibility testing. The FDA and EMA will likely face increasing pressure to approve diagnostics that account for heteroresistance, and clinical trial designs will need to incorporate endpoints that assess treatment failure beyond simple MIC-based susceptibility. The era of treating bacteria as a homogenous population is over; the future of antibiotic therapy lies in understanding and addressing their inherent heterogeneity.